无异型增生的巴雷特食管持续存在并不能预防进展为腺癌。 - Suppr

Persistence of Nondysplastic Barrett's Esophagus Is Not Protective Against Progression to Adenocarcinoma.

作者信息

Krishnamoorthi Rajesh, Ramos Guilherme Piovezani, Crews Nicholas, Johnson Michele, Dierkhising Ross, Shi Qian, Ginos Brenda, Wang Kenneth, Katzka David, Buttar Navtej, Iyer Prasad G

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

出版信息

Clin Gastroenterol Hepatol. 2017 Jun;15(6):950-952. doi: 10.1016/j.cgh.2017.02.019. Epub 2017 Feb 24.

DOI:10.1016/j.cgh.2017.02.019

PMID:28238955

Abstract

摘要

相似文献

Persistence of Nondysplastic Barrett's Esophagus Is Not Protective Against Progression to Adenocarcinoma.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):950-952. doi: 10.1016/j.cgh.2017.02.019. Epub 2017 Feb 24.

[Poorly differentiated endocrine carcinoma and adenocarcinoma on Barrett's esophagus].

Gastroenterol Clin Biol. 2005 May;29(5):613-4. doi: 10.1016/s0399-8320(05)82141-4.

Barrett's esophagus and esophageal adenocarcinoma. Endoscopic and histologic surveillance.

Scand J Gastroenterol. 1993 Mar;28(3):193-6. doi: 10.3109/00365529309096070.

High grade dysplasia/esophageal adenocarcinoma in short segment Barrett's esophagus.

South Med J. 1997 Aug;90(8):828-30. doi: 10.1097/00007611-199708000-00011.

Adenomas arising in Barrett's esophagus with adenocarcinoma. Report of three cases.

Pathol Res Pract. 1992 Dec;188(8):1028-32. doi: 10.1016/S0344-0338(11)81247-1.

Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.

Am J Gastroenterol. 2002 Aug;97(8):1930-6. doi: 10.1111/j.1572-0241.2002.05902.x.

Barrett's Esophagus and the Prevention of Esophageal Adenocarcinoma.

Gastrointest Endosc Clin N Am. 2017 Jul;27(3):xiii-xiv. doi: 10.1016/j.giec.2017.04.002. Epub 2017 May 5.

Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus.

Gastrointest Endosc. 1993 Jan-Feb;39(1):73-6. doi: 10.1016/s0016-5107(93)70017-6.

Risk factors, DNA damage, and disease progression in Barrett's esophagus.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5. doi: 10.1158/1055-9965.EPI-04-0509.

Esophagogastric junctional adenocarcinoma originating from endoscopically unrecognizable Barrett's epithelium.

Dis Esophagus. 2016 Nov;29(8):1164-1166. doi: 10.1111/dote.12396. Epub 2015 Jul 30.

引用本文的文献

Improving clinical outcomes of Barrett's esophagus with high dose proton pump inhibitors and cryoablation.

Ann Med. 2023 Dec;55(1):1256-1264. doi: 10.1080/07853890.2023.2191002.

Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

Clin Gastroenterol Hepatol. 2022 Feb;20(2):e31-e50. doi: 10.1016/j.cgh.2021.04.032. Epub 2021 Apr 23.

What is the optimal surveillance strategy for non-dysplastic Barrett's esophagus?

Curr Treat Options Gastroenterol. 2020 Sep;18(3):369-383. doi: 10.1007/s11938-020-00297-9. Epub 2020 Jun 25.

Optimal Timing for Cancer Screening and Adaptive Surveillance Using Mathematical Modeling.

Cancer Res. 2021 Feb 15;81(4):1123-1134. doi: 10.1158/0008-5472.CAN-20-0335. Epub 2020 Dec 8.

Predictors of Progression in Barrett's Esophagus.

Curr Treat Options Gastroenterol. 2019 Mar;17(1):18-31. doi: 10.1007/s11938-019-00214-9.

Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.

World J Gastroenterol. 2019 Jan 14;25(2):233-244. doi: 10.3748/wjg.v25.i2.233.

Editorial: Best Practices in Surveillance of Barrett's Esophagus.

Am J Gastroenterol. 2017 Jul;112(7):1056-1060. doi: 10.1038/ajg.2017.117.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Persistence of Nondysplastic Barrett's Esophagus Is Not Protective Against Progression to Adenocarcinoma.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):950-952. doi: 10.1016/j.cgh.2017.02.019. Epub 2017 Feb 24.

[Poorly differentiated endocrine carcinoma and adenocarcinoma on Barrett's esophagus].

Gastroenterol Clin Biol. 2005 May;29(5):613-4. doi: 10.1016/s0399-8320(05)82141-4.

Barrett's esophagus and esophageal adenocarcinoma. Endoscopic and histologic surveillance.

Scand J Gastroenterol. 1993 Mar;28(3):193-6. doi: 10.3109/00365529309096070.

High grade dysplasia/esophageal adenocarcinoma in short segment Barrett's esophagus.

South Med J. 1997 Aug;90(8):828-30. doi: 10.1097/00007611-199708000-00011.

Adenomas arising in Barrett's esophagus with adenocarcinoma. Report of three cases.

Pathol Res Pract. 1992 Dec;188(8):1028-32. doi: 10.1016/S0344-0338(11)81247-1.

Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.

Am J Gastroenterol. 2002 Aug;97(8):1930-6. doi: 10.1111/j.1572-0241.2002.05902.x.

Barrett's Esophagus and the Prevention of Esophageal Adenocarcinoma.

Gastrointest Endosc Clin N Am. 2017 Jul;27(3):xiii-xiv. doi: 10.1016/j.giec.2017.04.002. Epub 2017 May 5.

Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus.

Gastrointest Endosc. 1993 Jan-Feb;39(1):73-6. doi: 10.1016/s0016-5107(93)70017-6.

Risk factors, DNA damage, and disease progression in Barrett's esophagus.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5. doi: 10.1158/1055-9965.EPI-04-0509.

Esophagogastric junctional adenocarcinoma originating from endoscopically unrecognizable Barrett's epithelium.

Dis Esophagus. 2016 Nov;29(8):1164-1166. doi: 10.1111/dote.12396. Epub 2015 Jul 30.

引用本文的文献

Improving clinical outcomes of Barrett's esophagus with high dose proton pump inhibitors and cryoablation.

Ann Med. 2023 Dec;55(1):1256-1264. doi: 10.1080/07853890.2023.2191002.

Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

Clin Gastroenterol Hepatol. 2022 Feb;20(2):e31-e50. doi: 10.1016/j.cgh.2021.04.032. Epub 2021 Apr 23.

What is the optimal surveillance strategy for non-dysplastic Barrett's esophagus?

Curr Treat Options Gastroenterol. 2020 Sep;18(3):369-383. doi: 10.1007/s11938-020-00297-9. Epub 2020 Jun 25.

Optimal Timing for Cancer Screening and Adaptive Surveillance Using Mathematical Modeling.

Cancer Res. 2021 Feb 15;81(4):1123-1134. doi: 10.1158/0008-5472.CAN-20-0335. Epub 2020 Dec 8.

Predictors of Progression in Barrett's Esophagus.

Curr Treat Options Gastroenterol. 2019 Mar;17(1):18-31. doi: 10.1007/s11938-019-00214-9.

Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.

World J Gastroenterol. 2019 Jan 14;25(2):233-244. doi: 10.3748/wjg.v25.i2.233.

Editorial: Best Practices in Surveillance of Barrett's Esophagus.

Am J Gastroenterol. 2017 Jul;112(7):1056-1060. doi: 10.1038/ajg.2017.117.

Persistence of Nondysplastic Barrett's Esophagus Is Not Protective Against Progression to Adenocarcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献